Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Table 3 Treatment-related adverse events during pembrolizumab therapy

Adverse event	All grades N (%)	Grade ≥ 3 N (%)
Fatigue	3 (19)
Rash, maculo-papular^a	2 (13)^a
Hypothyroidism^a	2 (13)^a
Anorexia	2 (13)
Colitis^a	1 (6)^a	1 (6)^a
Pneumonitis^a	1 (6)^a	1 (6)^a
Dyspnea^a	1 (6)^a
Arthralgia^a	1 (6)^a
Myalgia^a	1 (6)^a
Nausea	1 (6)
Mucositis oral	1 (6)
Dry skin	1 (6)
Anemia	1 (6)
Alanine aminotransferase increased	1 (6)
Aspartate aminotransferase increased	1 (6)

^aImmune-related adverse event (only one patient with maculo-papular rash and hypothyroidism had immune-related adverse event)